Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis
Saad Aslam(Optum (United States)), Gary H. Lyman(University of Washington), Amy Anderson(Optum (United States)), Lincy S. Lal(Optum (United States)), Elizabeth J. Bell(University of Vermont), Jesse Peterson-Brandt, Edward Li(Sanden (Japan))
Cited by 8
Related Papers
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
|Journal of Clinical Oncology|2015|1k
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
|Journal of Clinical Oncology|2015|903
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
|CA A Cancer Journal for Clinicians|2015|737
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
|Journal of Clinical Oncology|2016|654